{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/ALNY/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-16T05:21:39.834Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":8564,"canonical_name":"ALNYLAM PHARMACEUTICALS, INC.","cik":"0001178670","uei":null,"lei":null,"duns":null,"ticker":"ALNY"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":18,"clinical":19},"count":37,"timeline":[{"ts":"2026-10-06","kind":"sec.filing","form_type":"4","title":"4 — ALNYLAM PHARMACEUTICALS, INC. — 2026-10-06","url_slug":"/sec/cik-0001178670/4/0001178670-26-000068","accession_number":"0001178670-26-000068","importance":30},{"ts":"2026-10-02","kind":"sec.filing","form_type":"144","title":"144 — ALNYLAM PHARMACEUTICALS, INC. — 2026-10-02","url_slug":"/sec/cik-0001178670/144/0001959173-26-007216","accession_number":"0001959173-26-007216","importance":30},{"ts":"2026-09-22","kind":"sec.filing","form_type":"4","title":"4 — ALNYLAM PHARMACEUTICALS, INC. — 2026-09-22","url_slug":"/sec/cik-0001178670/4/0001178670-26-000065","accession_number":"0001178670-26-000065","importance":30},{"ts":"2026-09-04","kind":"clinical.trial","reporter":"Alnylam Pharmaceuticals","title":"A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT07636811","excerpt":"[\"Down Syndrome-Associated Alzheimer's Disease (DS-AD)\"]","importance":45},{"ts":"2026-09-03","kind":"clinical.trial","reporter":"Alnylam Pharmaceuticals","title":"A Study to Evaluate ALN-6222 in Participants With Obesity","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT07624071","excerpt":"[\"Obesity\"]","importance":30},{"ts":"2026-07-30","kind":"sec.filing","form_type":"10-Q","title":"10-Q — ALNYLAM PHARMACEUTICALS, INC. — 2026-07-30","url_slug":"/sec/cik-0001178670/10-q/0001178670-26-000062","accession_number":"0001178670-26-000062","importance":45},{"ts":"2026-07-30","kind":"sec.filing","form_type":"8-K","title":"8-K — ALNYLAM PHARMACEUTICALS, INC. — 2026-07-30","url_slug":"/sec/cik-0001178670/8-k/0001178670-26-000060","accession_number":"0001178670-26-000060","importance":35},{"ts":"2026-06-03","kind":"sec.filing","form_type":"3","title":"3 — ALNYLAM PHARMACEUTICALS, INC. — 2026-06-03","url_slug":"/sec/cik-0001178670/3/0001178670-26-000046","accession_number":"0001178670-26-000046","importance":30},{"ts":"2026-06-03","kind":"sec.filing","form_type":"4","title":"4 — ALNYLAM PHARMACEUTICALS, INC. — 2026-06-03","url_slug":"/sec/cik-0001178670/4/0001178670-26-000047","accession_number":"0001178670-26-000047","importance":30},{"ts":"2026-06-01","kind":"sec.form144","reporter":"PYOTT DAVID E I","title":"Director","shares":3830,"usd_value":1147123,"security_title":"Common","approx_sale_date":"2026-06-01","accession_number":"0001969223-26-000618","importance":40.22942466},{"ts":"2026-06-01","kind":"sec.insider.s","reporter":"PYOTT DAVID E I","title":null,"shares":1222,"price_per_share":299.87,"usd_value":366441,"security_title":"Common Stock","importance":35.36644114},{"ts":"2026-06-01","kind":"sec.insider.s","reporter":"PYOTT DAVID E I","title":null,"shares":1175,"price_per_share":298.91,"usd_value":351219,"security_title":"Common Stock","importance":35.35121925},{"ts":"2026-06-01","kind":"sec.insider.s","reporter":"PYOTT DAVID E I","title":null,"shares":921,"price_per_share":297.71,"usd_value":274191,"security_title":"Common Stock","importance":35.27419091},{"ts":"2026-06-01","kind":"sec.insider.s","reporter":"PYOTT DAVID E I","title":null,"shares":495,"price_per_share":300.72,"usd_value":148856,"security_title":"Common Stock","importance":35.1488564},{"ts":"2026-06-01","kind":"sec.insider.s","reporter":"PYOTT DAVID E I","title":null,"shares":17,"price_per_share":302.65,"usd_value":5145,"security_title":"Common Stock","importance":35.00514505},{"ts":"2026-06-01","kind":"sec.insider.m","reporter":"PYOTT DAVID E I","title":null,"shares":3830,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-14","kind":"clinical.trial","reporter":"Alnylam Pharmaceuticals","title":"Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07181109","excerpt":"[\"High Risk Cardiovascular Disease\",\"Hypertension\",\"High Cardiovascular Risk\"]","importance":60},{"ts":"2026-05-14","kind":"clinical.trial","reporter":"Alnylam Pharmaceuticals","title":"TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07052903","excerpt":"[\"Transthyretin Amyloidosis With Cardiomyopathy\"]","importance":60},{"ts":"2026-05-14","kind":"clinical.trial","reporter":"Alnylam Pharmaceuticals","title":"TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07223203","excerpt":"[\"Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy\",\"hATTR-PN\"]","importance":60},{"ts":"2026-05-14","kind":"clinical.trial","reporter":"Alnylam Pharmaceuticals","title":"A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT07553442","excerpt":"[\"Hypertension\"]","importance":45},{"ts":"2026-05-14","kind":"clinical.trial","reporter":"Alnylam Pharmaceuticals","title":"A Study to Evaluate ALN-2232 in Participants With Obesity","security_title":"PHASE1,PHASE2","status":"RECRUITING","accession_number":"NCT07463846","excerpt":"[\"Obesity\"]","importance":45},{"ts":"2026-05-14","kind":"clinical.trial","reporter":"Alnylam Pharmaceuticals","title":"A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)","security_title":"PHASE1,PHASE2","status":"RECRUITING","accession_number":"NCT06659640","excerpt":"[\"Hereditary Hemorrhagic Telangiectasia\"]","importance":45},{"ts":"2026-05-14","kind":"clinical.trial","reporter":"Alnylam Pharmaceuticals","title":"A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT07465224","excerpt":"[\"Type 2 Diabetes Mellitus (T2DM)\"]","importance":45},{"ts":"2026-05-14","kind":"clinical.trial","reporter":"Alnylam Pharmaceuticals","title":"A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM","security_title":"PHASE1,PHASE2","status":"RECRUITING","accession_number":"NCT06845202","excerpt":"[\"Obese or Overweight Healthy Volunteers\",\"Type 2 Diabetes Mellitus (T2DM)\"]","importance":45},{"ts":"2026-05-14","kind":"clinical.trial","reporter":"Alnylam Pharmaceuticals","title":"HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB","security_title":"PHASE2","status":"NOT_YET_RECRUITING","accession_number":"NCT07575308","excerpt":"[\"Von Willebrand Disease (VWD)\",\"Heavy Menstrual Bleeding (HMB)\"]","importance":45},{"ts":"2026-05-14","kind":"sec.filing","form_type":"4","title":"4 — ALNYLAM PHARMACEUTICALS, INC. — 2026-05-14","url_slug":"/sec/cik-0001178670/4/0001178670-26-000017","accession_number":"0001178670-26-000017","importance":30},{"ts":"2026-05-14","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — ALNYLAM PHARMACEUTICALS, INC. — 2026-05-14","url_slug":"/sec/cik-0001178670/schedule-13g-a/0001422848-26-000050","accession_number":"0001422848-26-000050","importance":30},{"ts":"2026-05-14","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — ALNYLAM PHARMACEUTICALS, INC. — 2026-05-14","url_slug":"/sec/cik-0001178670/schedule-13g-a/0001422849-26-000061","accession_number":"0001422849-26-000061","importance":30},{"ts":"2026-05-14","kind":"clinical.trial","reporter":"Alnylam Pharmaceuticals","title":"A Study to Evaluate ALN-4285 in Adult Healthy Volunteers","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT07295717","excerpt":"[\"Healthy Volunteers\"]","importance":30},{"ts":"2026-05-14","kind":"clinical.trial","reporter":"Alnylam Pharmaceuticals","title":"A Study to Evaluate ALN-4915 in Adult Healthy Volunteers","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT07535606","excerpt":"[\"Healthy Volunteers\"]","importance":30},{"ts":"2026-05-13","kind":"sec.insider.m","reporter":"SCHULMAN AMY W","title":null,"shares":11250,"price_per_share":70.2,"usd_value":789750,"security_title":"Common Stock","importance":15.78975},{"ts":"2026-05-07","kind":"clinical.trial","reporter":"Alnylam Pharmaceuticals","title":"A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT05231785","excerpt":"[\"Early-Onset Alzheimer Disease\"]","importance":30},{"ts":"2026-05-01","kind":"clinical.trial","reporter":"Alnylam Pharmaceuticals","title":"A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT06600321","excerpt":"[\"Advanced Hepatocellular Carcinoma\",\"Metastatic Hepatocellular Carcinoma\"]","importance":30},{"ts":"2026-04-30","kind":"clinical.trial","reporter":"Alnylam Pharmaceuticals","title":"A Study to Evaluate Zilebesiran in Japanese Patients With Mild to Moderate Hypertension","security_title":"PHASE1,PHASE2","status":"COMPLETED","accession_number":"NCT06423352","excerpt":"[\"Mild to Moderate Hypertension\"]","importance":45},{"ts":"2026-04-27","kind":"clinical.trial","reporter":"Alnylam Pharmaceuticals","title":"ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)","security_title":null,"status":"RECRUITING","accession_number":"NCT04883905","excerpt":"[\"Acute Hepatic Porphyria\"]","importance":25},{"ts":"2026-04-24","kind":"clinical.trial","reporter":"Alnylam Pharmaceuticals","title":"BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)","security_title":null,"status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT04982393","excerpt":"[\"Primary Hyperoxaluria Type 1\"]","importance":25},{"ts":"2026-04-24","kind":"clinical.trial","reporter":"Alnylam Pharmaceuticals","title":"DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting","security_title":null,"status":"RECRUITING","accession_number":"NCT07358078","excerpt":"[\"Transthyretin Amyloidosis With Cardiomyopathy\"]","importance":25}]}